MESA LABORATORIES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 90.42 USD | +3.07% |
|
+2.54% | -13.70% |
| Jul. 01 | Mesa Laboratories, Inc.(NasdaqGS:MLAB) added to Russell 3000 Value Index | CI |
| Jul. 01 | Mesa Laboratories, Inc.(NasdaqGS:MLAB) added to Russell 2000 Value Index | CI |
Financials (USD)
| Sales 2025 * | 234M | Sales 2026 * | 247M | Capitalization | 489M |
|---|---|---|---|---|---|
| Net income 2025 * | 3M | Net income 2026 * | 4M | EV / Sales 2025 * | 2.09 x |
| Net cash position 2025 * | - | Net cash position 2026 * | - | EV / Sales 2026 * | 1.98 x |
| P/E ratio 2025 * |
127
x | P/E ratio 2026 * |
103
x | Employees | 736 |
| Yield 2025 * |
0.71% | Yield 2026 * |
0.71% | Free-Float | 94.91% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +3.07% | ||
| 1 week | +2.54% | ||
| Current month | +4.21% | ||
| 1 month | -2.69% | ||
| 3 months | -9.40% | ||
| 6 months | -6.91% | ||
| Current year | -13.70% |
1 week
84.32
91.13
1 month
83.68109.35
Current year
83.68123.79
1 year
82.86145.46
3 years
82.86333.42
5 years
82.86333.42
10 years
54.60333.42
| Managers | Title | Age | Since |
|---|---|---|---|
Gary Owens
CEO | Chief Executive Officer | 56 | 17-03-19 |
John Sullivan
CHM | Chairman | 71 | 04-09-30 |
John Sakys
DFI | Director of Finance/CFO | 55 | 12-10-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Sullivan
CHM | Chairman | 71 | 04-09-30 |
Mark Capone
BRD | Director/Board Member | 61 | Jan. 04 |
R. Tripeny
BRD | Director/Board Member | 65 | 22-06-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-03 | 90.42 | +3.07% | 17,631 |
| 24-07-02 | 87.73 | -0.81% | 44,695 |
| 24-07-01 | 88.45 | +1.94% | 61,590 |
| 24-06-28 | 86.77 | +2.15% | 212,172 |
| 24-06-27 | 84.94 | -3.67% | 75,831 |
Delayed Quote Nasdaq, July 03, 2024 at 01:00 pm EDT
More quotes
Mesa Laboratories, Inc. is a multinational manufacturer, developer, and seller of life sciences tools and critical quality control solutions. Its segments include Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. Its Clinical Genomics segment develops, manufactures, and sells throughput genetic analysis tools used by labs to perform clinical genomic testing in several therapeutic areas. Its Sterilization and Disinfection Control segment manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization and disinfection processes. Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Calibration Solutions segment develops, manufactures, and sells quality control products used to measure or calibrate temperature, pressure, pH, humidity, and other such parameters.
Calendar
2024-07-31
- Q1 2025 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
90.42
USD
Average target price
118
USD
Spread / Average Target
+30.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.70% | 489M | |
| -7.03% | 178B | |
| -6.32% | 98.95B | |
| -6.15% | 66.14B | |
| -10.62% | 44.11B | |
| +8.34% | 43.82B | |
| +12.14% | 42.07B | |
| +11.64% | 28.92B | |
| +18.22% | 24.69B | |
| -8.87% | 23.38B |
- Stock Market
- Equities
- MLAB Stock
